Arbutus Biopharma Corp (ABUS)

Import this data to Google Sheets with:

=jivedata("ABUS","financials")

Full statements spill as a table. For one cell: =jivedata("ABUS","Revenue") or =jivedata("ABUS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Arbutus Biopharma Corp

ABUS • CIK 0001447028

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-78,103	$-76,319	$-38,160	$148,995
Revenues	$18,141	$6,171	$14,083	$181,720
Research and Development Expense	$73,700	$54,037	$25,241	$17,802
General and Administrative Expense	$22,475	$22,108	$15,893	$16,489
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$69	$2,625	$-1,830	$-1,967
Restructuring Charges	$1,100	$3,720	$12,939	$401
Operating Expenses	$96,244	$82,490	$52,243	$32,725
Investment Income, Interest	$5,688	$6,585	$4,068	$3,486
Gain (Loss) on Disposition of Property Plant Equipment	$20	$0	$674	$674
InterestExpenseNonoperating	—	$137	$97	$76
Foreign Currency Transaction Gain (Loss), before Tax	$25	$-49	$14	$-25
Nonoperating Income (Expense)	$5,254	$6,399	$4,659	$4,059
Net Income (Loss) Attributable to Parent	$-72,849	$-69,920	$-33,501	$153,054
Weighted Average Number of Shares Outstanding, Basic	165,960,379	185,608,874	191,599,600	196,095,086
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$2,067	$286	$37	$37
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-70,782	$-69,634	$-33,464	$152,997

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$26,285	$36,330	$18,008	$19,171
Short-term Investments	$99,718	$86,293	$73,463	$73,463
Property, Plant and Equipment, Net	$4,674	$3,309	$32	$10
Accounts Receivable, after Allowance for Credit Loss, Current	$1,776	$2,409	$1,447	$369
Long-term Investments	$6,284	$0	$0	$0
Prepaid Expense and Other Assets, Current	$4,248	$2,284	$1,538	$1,516
Operating Lease, Right-of-Use Asset	$1,416	$1,048	$0	$0
Assets, Current	$132,027	$127,316	$94,456	$273,883
Other Assets, Noncurrent	$0	$34	$130	$132
Assets	$144,401	$131,707	$94,618	$274,025
Deferred Revenue, Noncurrent	$0	$2,863	$0	$0
Business Combination, Contingent Consideration, Liability, Noncurrent	$7,600	$10,225	$8,395	$8,817
Operating Lease, Liability, Noncurrent	$1,343	$806	$199	$0
Liabilities	$38,383	$34,341	$18,042	$15,292
Accounts Payable and Accrued Liabilities, Current	$10,271	$7,564	$5,459	$2,850
Deferred Revenue, Current	$11,791	$7,571	$0	$0
Operating Lease, Liability, Current	$425	$483	$547	$514
Liabilities, Current	$22,487	$15,618	$6,006	$3,364
Common Stock, Value, Issued	$1,349,821	$1,410,025	$1,421,429	$1,448,177
Additional Paid in Capital	$81,270	$82,048	$83,318	$74,321
Retained Earnings (Accumulated Deficit)	$-1,276,652	$-1,346,572	$-1,380,073	$-1,215,521
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-48,421	$-48,135	$-48,098	$-48,244
Stockholders' Equity Attributable to Parent	$106,018	$97,366	$76,576	$258,733
Common Stock, Shares, Issued	169,867,414	189,963,492	192,531,225	197,634,118

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-72,849	$-69,920	$-33,501	$153,054
Net Cash Provided by (Used in) Operating Activities	$-85,936	$-64,850	$-39,637	$-24,625
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$25	$-49	$14	$-25
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-4,491	$10,045	$-18,322	$-18,241
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$26,285	$36,330	$18,008	$4,638
Depreciation	$1,404	$1,380	$363	$363
Payments to Acquire Investments	$80,509	$141,509	$140,061	$114,309
Gain (Loss) on Disposition of Property Plant Equipment	$20	$0	$674	$674
Proceeds from Sale, Maturity and Collection of Investments	$132,270	$164,639	$155,277	$103,112
Share-based Payment Arrangement, Noncash Expense	$9,301	$8,986	$6,953	$5,509
Proceeds from Sale of Property, Plant, and Equipment	$20	$0	$364	$355
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$69	$2,625	$-1,830	$-1,967
Payments to Acquire Property, Plant, and Equipment	$1,008	$182	$0	$0
Net Cash Provided by (Used in) Investing Activities	$50,773	$22,948	$15,580	$-10,842
Restructuring, Settlement and Impairment Provisions	—	$167	$2,811	$0
Accretion (Amortization) of Discounts and Premiums, Investments	$2,196	$3,135	$2,349	$1,638
Increase (Decrease) in Accounts Receivable	$424	$633	$-1,375	$-1,069
Increase (Decrease) in Prepaid Expense and Other Assets	$943	$-2,298	$-1,698	$-2,358
Proceeds from Stock Options Exercised	$260	$7,477	$5,540	$17,113
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$-5,758	$-2,707	$-2,105	$-1,658
Proceeds from Stock Plans	$535	$396	$181	$138
Increase (Decrease) in Deferred Revenue	$-10,664	$-1,357	$-10,434	$0
Net Cash Provided by (Used in) Financing Activities	$30,647	$51,996	$5,721	$17,251
Increase (Decrease) in Other Operating Liabilities	$-444	$-430	$-557	$-550

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("ABUS","financials")

Full statements spill as a table. For one cell: =jivedata("ABUS","Revenue") or =jivedata("ABUS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.